IRCT20180310039019N1已完成未知
Clinical evaluation of the SSSLTVPWY peptide labeled with 99m TC to determine HER2 status for the treatment of patients with Breast Cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Female
入选标准
- •Primary breast cancer
- •Size greater than 2cm
- •Without any history of biopsy
排除标准
- •Renal failure
- •Liver dysfunction
研究者
相似试验
招募中
Unknown
Clinical evaluation of the SSSLTVSPWY peptide labeled with 68GaBreast cancer.Malignant neoplasm of breast of unspecified site, femaleC50.91IRCT20230312057691N1Mazandaran University of Medical Sciences25
已完成
1 期
Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.Completely resected NSCLC, stage IA with vascular invasion and stage IB/II with WT1 antigen positive.JPRN-UMIN000010027Osaka University Graduate School of Medicine, Department of Functional Diagnosis237
已完成
2 期
A phase 2 clinical trial of personalized peptide vaccination for castration-resistant prostate cancer (CRPC) patients with slight bone marrow suppressioCastration-resistant prostate cancerJPRN-UMIN000019802Cancer Vaccine Center, Kurume University School of medicine35
已完成
2 期
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000019879Cancer Vaccine Center, Kurume University School of medicine35
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35